Novabay Pharmaceuticals Inc Short ratio
Cos'è Short ratio di Novabay Pharmaceuticals Inc?
Short ratio di Novabay Pharmaceuticals Inc è 0.58
Qual è la definizione di Short ratio?
Short ratio è il numero di azioni vendute breve diviso per il volume medio giornaliero.
Short ratio is calculated by dividing the number of shares sold short by the average daily trading volume, generally over the last 30 trading days. The ratio represents the number of days it takes short sellers on average to repurchase all the borrowed shares. The ratio is used by both fundamental and technical traders to identify trends.
The percentage represents the number of days it takes short sellers on average to repurchase all the borrowed shares. Short selling is the practice of selling securities or other financial instruments that are not currently owned, and subsequently repurchasing them. In the event of an interim price decline, the short seller profits, since the cost of (re)purchase is less than the proceeds received upon the initial (short) sale. Conversely, the short position closes out at a loss if the price of a shorted instrument rises prior to repurchase. A high short ratio can be an indicator that there will be some buying pressure on the security that would increase its price.
Short ratio di aziende nel Health Care settore su NYSEMKT rispetto a Novabay Pharmaceuticals Inc
Cosa fa Novabay Pharmaceuticals Inc?
novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across
Aziende con short ratio simili a Novabay Pharmaceuticals Inc
- L.S. Starrett Co ha Short ratio di 0.57
- J. Alexanders Inc ha Short ratio di 0.57
- Commerce Bancshares, (Missouri) ha Short ratio di 0.57
- Revelo Resources ha Short ratio di 0.57
- Cemtrex ha Short ratio di 0.57
- Tenaz Corp ha Short ratio di 0.57
- Novabay Pharmaceuticals Inc ha Short ratio di 0.58
- LSI Industries ha Short ratio di 0.59
- Alio Gold ha Short ratio di 0.59
- Gensource Potash ha Short ratio di 0.59
- Quintana Services ha Short ratio di 0.59
- Sylla Gold Corp ha Short ratio di 0.59
- Marvel Discovery ha Short ratio di 0.59